CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 684 enrolled
Drug / intervention
risankizumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02694523
NCT02694523Phase 3Completed
CompareCT.gov

BI 655066/ABBV-066 (Risankizumab) Versus Adalimumab in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Inadequate Adalimumab Treatment Response (IMMvent)

AbbVie·interventional·Posted Feb 29, 2016·Updated Jul 30, 2021

In Brief

A Phase 3 clinical trial evaluating risankizumab, adalimumab, and 2 other interventions for Psoriasis. Completed, enrolled 684 participants.

Detailed Summary

This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support registration for the treatment of moderate to severe chronic plaque psoriasis in adult patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
CollaboratorsBoehringer Ingelheim

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 29, 2016
Enrollment StartMar 1, 2016
Primary CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.3 years ago

Interventions

risankizumabdrug

Risankizumab administered by subcutaneous (SC) injection

adalimumabbiological

Adalimumab pre-filled syringe, administered by subcutaneous (SC) injection

placebo for risankizumabdrug

Placebo risankizumab administered by subcutaneous (SC) injection

placebo for adalimumabbiological

Placebo for adalimumab pre-filled syringe, administered by subcutaneous (SC) injection